NEW YORK – Dialysis company Neway said Thursday that it has entered a strategic lab services arrangement with Quest Diagnostics to speed dialysis lab testing and reduce testing costs for patients with end-stage renal disease (ESRD).
Under the terms of the agreement, Neway will use Quest's lab network to provide local testing services, enabling next-day results while also reducing sample transportation costs.
"The centralized dialysis laboratory specimen testing model has been around since the early 1990s with limited innovation," Neway Founder and CEO Bryan Thompson said in a statement. "The old model of generally relying on air transportation of dialysis laboratory specimens to a single US location is costly and can takes days for results. The 'new way' for dialysis laboratory testing is a decentralized network of laboratory locations that spans the nation."
"As a leader in cardiometabolic diagnostic solutions, including in kidney disease, Quest understands the unique challenges patients with ESRD face and the criticality of rapid testing that never compromises on quality," Mouris Saghir, vice president and general manager for the Quest Diagnostics National Cardiometabolic Center of Excellence at Cleveland HeartLab, said in a statement. "Working together with Neway, we will address these challenges and expedite test results while maintaining the highest level of quality for patients with ESRD."
Financial and other terms of the agreement were not disclosed.